W
WAVEMAN · COMPANY
AIDX · 20/20 Biolabs, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

AIDX

20/20 Biolabs, Inc.
PHARMA & BIOTECH · SERVICES-TESTING LABORATORIES · CIK 0001139685
ACTIVIST 13D☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
12
13F, latest reported quarter
REVENUE GROWTH
+16.7%
XBRL, annual
NET MARGIN
-182.8%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
12 funds added or opened last quarter
below 79% of Pharma & Biotech
REVENUE
+16.7% year over year
more than 66% of Pharma & Biotech
MARGIN
-182.8% net margin
below 71% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
1.2% of shares outstanding short · 1.3 days to cover · settled 2026-07-31
below 70% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Jonathan M Cohen disclosed a 5%+ stake (16.8%) in the last six months.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -97.5%
-97.5%12M
-98%-66%-33%+0%2026-022026-032026-042026-052026-072026-08 2026-03-10 · Jonathan M Cohen filed a 5%+ stake (16.8%)
13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
An activist crossed the 5% line with declared intent.
The record shows 12 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for 20/20 Biolabs, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE

no insider purchases or sales on record

0 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Cresset Asset Management, LLC
240,122.0 sh
$132.0K
VANGUARD FIDUCIARY TRUST CO
52,087.0 sh
$28.6K
GEODE CAPITAL MANAGEMENT, LLC
49,141.0 sh
$27.0K
Atlantic Union Bankshares Corp
35,099.0 sh
$19.3K
VANGUARD CAPITAL MANAGEMENT LLC
24,530.0 sh
$13.5K
5%+ owners
13D = intent to influence · 13G = passive
Jonathan M Cohen
ACTIVIST 13D · 2026-03-10
16.8%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-12
REVENUE$2.0M$1.8M
GROSS PROFIT$604.5K$360.3K
OPERATING INCOME$-3.3M$-5.7M
NET INCOME$-3.7M$-5.6M
EPS (DILUTED)-0.76-1.16
OPERATING CASH FLOW$-1.9M$-2.6M
CASH$1.0M$1.8M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →